These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30067910)

  • 1. Peptide-Functionalized Nanoinhibitor Restrains Brain Tumor Growth by Abrogating Mesenchymal-Epithelial Transition Factor (MET) Signaling.
    Wu Y; Fan Q; Zeng F; Zhu J; Chen J; Fan D; Li X; Duan W; Guo Q; Cao Z; Briley-Saebo K; Li C; Tao X
    Nano Lett; 2018 Sep; 18(9):5488-5498. PubMed ID: 30067910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.
    Meng X; Zhao Y; Han B; Zha C; Zhang Y; Li Z; Wu P; Qi T; Jiang C; Liu Y; Cai J
    Nat Commun; 2020 Jan; 11(1):594. PubMed ID: 32001707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
    Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated Polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma.
    Jiang Y; Lv L; Shi H; Hua Y; Lv W; Wang X; Xin H; Xu Q
    Colloids Surf B Biointerfaces; 2016 Nov; 147():242-249. PubMed ID: 27518456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MET for glioma therapy.
    Awad AJ; Burns TC; Zhang Y; Abounader R
    Neurosurg Focus; 2014 Dec; 37(6):E10. PubMed ID: 25434379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of mesenchymal-epithelial transition factor (c-Met) expression using an optical imaging system.
    Kim EM; Park EH; Cheong SJ; Lee CM; Jeong HJ; Kim DW; Lim ST; Sohn MH
    Bioconjug Chem; 2009 Jul; 20(7):1299-306. PubMed ID: 19534520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT.
    Kaushik NK; Kaushik N; Yoo KC; Uddin N; Kim JS; Lee SJ; Choi EH
    Biomaterials; 2016 May; 87():118-130. PubMed ID: 26921841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
    Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
    Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.
    Náger M; Santacana M; Bhardwaj D; Valls J; Ferrer I; Nogués P; Cantí C; Herreros J
    Cell Cycle; 2015; 14(22):3644-55. PubMed ID: 26654598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas.
    Liu C; Zhao Z; Gao H; Rostami I; You Q; Jia X; Wang C; Zhu L; Yang Y
    Nanotheranostics; 2019; 3(4):311-330. PubMed ID: 31687320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.
    Zhao Y; Sun Y; Zhang H; Liu X; Du W; Li Y; Zhang J; Chen L; Jiang C
    Int J Clin Exp Pathol; 2015; 8(4):3719-26. PubMed ID: 26097553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
    Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
    Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
    Lu KV; Chang JP; Parachoniak CA; Pandika MM; Aghi MK; Meyronet D; Isachenko N; Fouse SD; Phillips JJ; Cheresh DA; Park M; Bergers G
    Cancer Cell; 2012 Jul; 22(1):21-35. PubMed ID: 22789536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET in glioma: signaling pathways and targeted therapies.
    Cheng F; Guo D
    J Exp Clin Cancer Res; 2019 Jun; 38(1):270. PubMed ID: 31221203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.
    Olmez I; Zhang Y; Manigat L; Benamar M; Brenneman B; Nakano I; Godlewski J; Bronisz A; Lee J; Abbas T; Abounader R; Purow B
    Cancer Res; 2018 Aug; 78(15):4360-4369. PubMed ID: 29844123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LIM and SH3 protein 1 induces glioma growth and invasion through PI3K/AKT signaling and epithelial-mesenchymal transition.
    Zhong C; Li X; Tao B; Peng L; Peng T; Yang X; Xia X; Chen L
    Biomed Pharmacother; 2019 Aug; 116():109013. PubMed ID: 31146105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.